# Johnson & Johnson Phase 2 Sjögren's Data Show 96% of Patients Cite Dry Mouth > Johnson & Johnson's Phase 2 Sjögren's interviews found 96% of patients cited dry mouth, and the findings shaped the design of the ongoing Phase 3 DAFFODIL study. - Published: 2026-11-07T15:20:08+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-11-07/johnson-johnson-sjogrens-nipocalimab-dry-mouth - Source: [Stock Titan](https://www.stocktitan.net/news/JNJ/johnson-johnson-announces-new-phase-2-nipocalimab-study-data-in-goetdufy174b.html) ## Key takeaways - In Johnson & Johnson's Phase 2 DAHLIAS exit interviews, 96% of patients cited mouth dryness, followed by fatigue at 92% and eye dryness at 90%. - Of 163 DAHLIAS participants, 49 completed the blinded exit interviews, and 73.5% reported being satisfied or very satisfied with study treatment. - Johnson & Johnson has initiated the Phase 3 DAFFODIL study in adults with moderate-to-severe Sjögren's disease, assessing dryness, pain, fatigue and quality of life. [Johnson](https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc) & Johnson said on November 7, 2026 that patient experience data from its Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease show mouth dryness was the symptom improvement that mattered most to patients, cited by 96% of those surveyed. [Stock Titan](https://www.stocktitan.net/news/JNJ/johnson-johnson-announces-new-phase-2-nipocalimab-study-data-in-goetdufy174b.html) reported the findings, which are among 23 abstracts on nipocalimab to be presented at the American College of Rheumatology Convergence 2026. ## What The DAHLIAS Exit Interviews Found Johnson & Johnson, the New Brunswick-based pharmaceutical and medical technology group, said the interviews were conducted with participants after the Phase 2 study's treatment period. Of 163 DAHLIAS participants, 49, or 30.1%, completed the exit interviews while still blinded and pooled across treatment arms. The analysis used 60-minute, one-to-one semi-structured qualitative exit interviews conducted within two weeks after the 24-week treatment period, with blinded, independent researchers and thematic analysis. Five core symptoms were most frequently reported: mouth dryness at 96%, fatigue at 92%, eye dryness at 90%, joint pain at 73% and, among women, vaginal dryness at 49%. Nearly three-quarters of participants, 73.5%, reported being satisfied or very satisfied with study treatment. "Patients told us that Sjögren's disease affects nearly every aspect of daily life, with mouth dryness emerging as both the most frequently reported symptom and the symptom most often prioritized, among those asked, for improvement," said Ghaith Noaiseh, M.D., Associate Professor, Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center. Johnson & Johnson said the findings helped inform the design of the ongoing Phase 3 study of nipocalimab in Sjögren's disease. The company also cited previously reported Phase 2 data showing an improvement in objective salivary flow, at least a 50% increase from baseline, in more than twice as many patients in the high-dose nipocalimab group at 15 mg/kg compared with placebo, 33% versus 16%, at Week 24. ## Nipocalimab's Regulatory Designations According to akta.pro [company records](https://akta.pro/company-data), Johnson & Johnson was founded in 1886 and is headquartered in New Brunswick, with Joaquin Duato as Chairman of the Board and Chief Executive Officer. The same records list John C. Reed as Executive Vice President, Pharmaceuticals, R&D. Nipocalimab is the only Fc receptor blocker granted both Breakthrough Therapy Designation and Fast Track Designation by the U.S. Food and Drug Administration for the treatment of adults with moderate-to-severe Sjögren's disease, according to the company. ## Earlier Sjögren's And Arthritis Results On November 7, 2026, Stock Titan reported that Johnson & Johnson announced positive Phase 3 results for ICOTYDE in biologic-naive psoriatic arthritis patients, with 58% achieving ACR20 and 29% achieving ACR50 at Week 16, presented at ACR Convergence 2026. On November 1, 2026, TradingView reported positive 30-day results from a trial of Johnson & Johnson's Shockwave Javelin catheter, which achieved a 93.6% technical success rate in treating severely narrowed coronary arteries. ## The Phase 3 DAFFODIL Study Following the positive Phase 2 DAHLIAS results, Johnson & Johnson initiated the Phase 3 DAFFODIL study in adults with moderate-to-severe Sjögren's disease. The company said the study design assesses disease activity alongside dryness, pain, fatigue, quality of life and patient-perceived improvement. ## Companies in this story - [Johnson & Johnson Services, Inc. company profile](https://akta.pro/company-profiles/00033dv/johnson-johnson-services-inc) · website: https://www.jnj.com --- News for Agent · https://newsforagent.com/llms.txt